SDTM

This topic was already discussed in the SEND Forum in 2015, but there is no change till today. SD0007 is still an error. It fires for the DA dataset, if subjects are dispensed both tablets and capsule at the same visit. In this case there are two records per visit with DATESTCD= DISPAMT, but DASTRESU is TABLET and CAPSULE. In a "double blind / double dummy trial" tablet and capsule can be both: study medication or placebo. Therefore a specification via DACAT is not possible.

Hi,

Got a SUPPAE with the QNAM/QLABEL = AETRTEM /TREATMENT EMERGENT FLAG but the P21 validation rule says 'No Treatment Emergent info for Adverse Event'.

Why does my validation report have hits on this rule?

br Kirsten

I have downloaded the SDTM terminology from your website: https://www.pinnacle21.com/downloads/cdisc-terminology (latest 2018-03-30) and noticed that RACE codelist has

       <CodeList OID="CL.C74457.RACE" Name="Race" DataType="text" nciodm:CodeListExtensible="Yes">

but in NCI RACE is specified as

       <CodeList OID="CL.C74457.RACE" Name="Race" DataType="text" nciodm:ExtCodeID="C74457" nciodm:CodeListExtensible="No">

It is also the case for other versions.

Can I include device domains DI and DU with human clinical trial SDTM submission? My study captures some device information related to CT imaging.

I tried to include this in the submission package, but I got a "Dataset class not recognized" for DI. (DI is defined as special purpose domain in SDTM IG for medical devices)

DU was accepted as custom Findings domain

Thanks,

Saravanan

Hi, In recent TCG v4.0 and 4.1, FDA has guidance to map logically skipped items in QS domain. My company collected Coulmbia Suicide Rating Scale (C-SSRS) and there are Describe questions which are typically blank based on response for previous Y/N question. We haven't mapped this in the past, but looks like FDA guidance is to map these. Has anyone does this and any thoughts/issues doing it.

Thanks.

Hello!

I have a special study design and I need you advice. The study has a screening, then all subjects start to take drug A during the Run-in period. Then, before randomization, subjects are tested for a randomization criterion.

If they fail, the subjects do a special visit Run-in early termination (only for them) and are discontinued.

If they passed, they are randomized to A+B or A+C and they continue the study. The 2 study treatments to be compared are B and C.

Below Error is from v2.2.0 P21 report. Seems like usubjid are identical in DM and other dataset. Any particular reason?

USUBJID, SUB:SITEID    XXXX-XXXXX, null    SD0064    FDAC040    Subject is not present in DM domain

Hi,

I am getting SD0006 WARNING during Pinnacle21 v2.2.0 execution on SDTM datasets. But, this warning is missing when I add define with SDTM datasets during execution. Any particular reason. No change in data.

Thanks

Ajay

Hello,

I am wondering when TSPARMCD=TRT, how TSVALCD shoudl be populated in case a treatment is not present in the UNII database. Shoudl it be left empty while TSVCDREF and TSVCDVER populated?

Thanks

According to the SDTM IG for Medical Devises V1.0, DISEQ should be unique within a parameter within a device (SPDEVID) within dataset for DI domain, but for other domains, --SEQ should be unique within every subject/device combination within dataset.

Why does SD0005 always fire when SPDEVID is not unique wuithin a device, but unique within every subject/device combination?